Table 4.
Multiple linear regression analysis of parameters associated with FT3.
| Variable | No NAFLD (n = 506) | NAFLD (n = 353) | ||
|---|---|---|---|---|
| B | P | B | P | |
| Age | -0.016 | <0.01 | -0.023 | <0.01 |
| T2DM duration | / | / | / | / |
| BMI | 0.03 | <0.05 | / | / |
| SBP (mmHg) | / | / | / | / |
| DBP (mmHg) | / | / | / | / |
| FINS (pmol/L) | / | / | / | / |
| FCP (nmol/L) | / | / | / | / |
| 2h-CP (nmol/L) | / | / | / | / |
| ABG (mmol/L) | -0.039 | <0.01 | -0.300 | <0.01 |
| FBG (mmol/L) | / | / | / | / |
| 2hBG (mmol/L) | / | / | / | / |
| HbA1c | -0.069 | <0.01 | -0.075 | <0.01 |
| HOMA-IR | / | / | / | / |
| HOMA-β | / | / | / | / |
| TSH (mU/L) | -0.020 | <0.05 | -0.022 | <0.05 |
| FT4 (pmol/L) | / | / | -0.028 | <0.05 |
| ALT (U/L) | / | / | 0.006 | <0.01 |
| AST (U/L) | / | / | / | / |
| GGT (U/L) | / | / | 0.003 | <0.05 |
| UN (mmol/L) | -0.041 | <0.01 | / | / |
| CR (μmol/L) | / | / | -0.005 | <0.01 |
| UA (μmol/L) | / | / | / | / |
| TG (mmol/L) | -0.006 | <0.05 | / | / |
| TC (mmol/L) | / | / | 0.085 | <0.05 |
| HDL-C (mmol/L) | / | / | / | / |
| LDL-C (mmol/L) | 0.090 | <0.05 | 0.187 | <0.01 |
| GFR (mL min−1 1.73 m−2) | / | / | / | / |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FINS: fasting insulin; FCP: fasting C peptide; ABG: admission blood glucose; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; TSH: thyroid-stimulating hormone; FT3: free triiodothyronine; FT4: free four iodothyronine; ALT: alanine transferase; AST: aspartate aminotransferase; GGT: glutamyl transpeptidase; UN: urea nitrogen; CR: creatinine; UA: uric acid; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; GFR: glomerular filtration rate; CRP: C-reactive protein; 2hBG: 2 h blood glucose; 2hINS: 2 h insulin; 2h-CP: 2 h C peptide; HOMA-IR: homeostasis model assessment-insulin resistance; HOMA-β: homeostasis model assessment-β. P < 0.05 was considered statistically significant.